Leibniz Prize winner Jürgen Ruland is a Professor of Clinical Chemistry.
Leibniz Prize winner Jürgen Ruland is a Professor of Clinical Chemistry.
Image: Andreas Heddergott / TUM
  • Research news
  • Reading time: 2 MIN

Most important German research award for Prof. RulandCancer researcher receives Leibniz Prize

Prof. Jürgen Ruland, from TUM’s Rechts der Isar Hospital, will receive the 2021 Gottfried Wilhelm Leibniz Prize. The Professor of Clinical Chemistry is being honored for his outstanding scientific work in the field of immunology, which has led to a fundamentally new understanding of the signal transmission pathways in immune and cancer cells, as announced by the German Research Foundation (DFG). The most important German research award includes 2.5 million euros in prize money. The award winner can use this money for future research.

Prof. Ruland focuses on normal signaling processes in the immune system and those that are disrupted during illness. With his working group, he is investigating how immune cells recognize pathogens, initiate the immune defense, and how pathologically altered signals in blood cells lead to the development of cancer. The aim is to provide the basis for the therapeutic manipulation of the immune system. One of his most important scientific findings is an “emergency stop” switch for defective cells that he and his team discovered in 2017.

TUM President Prof. Thomas F. Hofmann paid tribute to the award winner’s outstanding work: “Prof. Ruland is one of the most important cancer researchers of our time. With his research, he tries to better understand the body’s self-healing powers at the molecular level and thus fight diseases such as leukemia and lymphoma. We are proud to have him in our ranks, because he embodies TUM’s high standards: Top international research combined with practical benefits for mankind.”

Prof. Ruland studied medicine in Giessen and Pittsburgh and received a doctorate in pharmacology. After medical and scientific work at TUM, the University of Freiburg, the Ontario Cancer Institute, and the AMGEN Research Institute of the University of Toronto, he headed a junior research group of the German Cancer Aid at TUM starting in 2003. He qualified as a professor of medicine in 2005 and was Professor of Molecular Immunology at TUM from 2010 to 2012. He has been a full professor of clinical chemistry since 2012. He is a member of the German National Academy of Sciences Leopoldina and the Bavarian Academy of Sciences and Humanities. Since 2018, he has been the spokesman for the DFG Collaborative Research Center 1335 “Aberrant Immune Signals in Cancer.”

Ruland has already received numerous awards and grants for his scientific work, including:

  • European Research Council Advanced Grant (2013 & 2019)
  • Paul-Martini Prize (2010)
  • Wilhelm-Warner Prize for cancer research (2010)
  • Science Award of the Arbeitsgemeinschaft für Internistische Onkologie (2007)
  • Artur-Pappenheim Prize of the German Society for Hematology and Medical Oncology (2006)

More information:

Two TUM researchers were also awarded the Leibniz Prize last year. A total of 23 TUM researchers including Prof. Ruland have been honored with Leibniz Prizes since 1986.

Corporate Communications Center

Technical University of Munich

Contacts to this article:

Prof. Dr. Jürgen Ruland
Technical University of Munich
Chair of Clinical Chemistry and Pathobiochemistry
Tel.: +49 89 4140 4751
j.ruland(at)tum.de

Article at tum.de

Prof. Florian Bassermann, Michael Heider and Vanesa Fernández (f.l.t.r.).

Medication-based starvation of cancer cells

Immunomodulatory drugs, including the Contergan derivatives lenalidomide and pomalidomide, have significantly improved the therapy of hematologic malignancies such as multiple myeloma. Researchers at the Technical...

Prof. Jürgen Ruland in conversation with employee

When hyperactive proteins trigger illnesses

Autoimmune diseases, in which the body's own immune system attacks healthy tissue, can be life-threatening and can impact all organs. A research team at the Technical University of Munich (TUM) has now found a possible...

Arbeiten mit Zellkulturen sind in der onkologischen Grundlagenforschung ein wichtiges Werkzeug. (Bild: A. Heddergott / TUM)

TUM coordinates two new Collaborative Research Centers

The Technical University of Munich (TUM) has taken on the role of coordinator in two new German Research Foundation Collaborative Research Centers (short SFB for german ‘Sonderforschungsbereich’), both of which are...

Prof. Jürgen Ruland (rechts) und Dr. Tim Wartewig haben mit ihrer neuen Studie einen neuen Ansatzpunkt für Therapien gegen Lymphdrüsenkrebs gefunden. (Bild: A. Heddergott / TUM)

Shut-off switch for lymphoma

A safety switch that automatically stops the device for example before it overheats are built into many electrical appliances. The body's cells are also equipped with this kind of "emergency stop" functions. They make sure...

Professor Jürgen Ruland und eine Mitarbeiterin betrachten die Ergebnisse einer Untersuchung.

New key players found in fighting fungi

Fungal infections are a serious health risk. They can be harmful especially to patients whose immune system is compromised through illness or chemotherapy. A team working at the Technical University of Munich (TUM) has...

Aufnahmen von Harnsäurekristallen: Harnsäure bildet nadelförmige Kristalle, die das Immunsystem aktivieren. (Bild: K. Neumann/TUM)

A braking system for immune responses

For the first time, researchers have identified a receptor on human cells that specifically recognizes crystals. It is found on immune cells and binds uric acid crystals, which trigger gout but also control immune...